Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 40

1.

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells.

Ushijima M, Ogata Y, Tsuda H, Akagi Y, Matono K, Shirouzu K.

Oncol Rep. 2014 Jan;31(1):19-26. doi: 10.3892/or.2013.2839. Epub 2013 Nov 8.

2.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
3.

Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.

Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.

Integr Cancer Ther. 2005 Jun;4(2):168-77.

PMID:
15911929
4.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
5.
6.

The present state of antineoplaston research (1).

Burzynski SR.

Integr Cancer Ther. 2004 Mar;3(1):47-58. Review.

PMID:
15035876
7.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
8.

Immune modulatory potentials of antineoplaston A-10 in breast cancer patients.

Badria F, Mabed M, El-Awadi M, Abou-Zeid L, Al-Nashar E, Hawas S.

Cancer Lett. 2000 Aug 31;157(1):57-63.

PMID:
10893443
9.

Potential utility of antineoplaston A-10 levels in breast cancer.

Badria F, Mabed M, Khafagy W, Abou-Zeid L.

Cancer Lett. 2000 Jul 3;155(1):67-70.

PMID:
10814881
10.

Efficacy of antineoplastons A10 and AS2-1.

Burzynski SR.

Mayo Clin Proc. 1999 Jun;74(6):641-2. No abstract available.

PMID:
10377942
11.

Synthesis of Mannich bases of antineoplaston A10 and their antitumor activity.

Choi BG, Seo HK, Chung BH, Choi SU, Lee CO.

Arch Pharm Res. 1994 Dec;17(6):467-9.

PMID:
10319160
12.

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.

Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD.

Mayo Clin Proc. 1999 Feb;74(2):137-45.

PMID:
10069350
13.

Synthesis of antineoplaston A10 analogs as potential antitumor agents.

Choi BG, Kim OY, Chung BH, Cho WJ, Cheon SH, Choi SU, Lee CO.

Arch Pharm Res. 1998 Apr;21(2):157-63.

PMID:
9875424
14.

Antineoplaston treatment for advanced hepatocellular carcinoma.

Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H.

Oncol Rep. 1998 Nov-Dec;5(6):1363-7.

PMID:
9769368
15.

Quick response of advanced cancer to chemoradiation therapy with antineoplastons.

Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y, Nagamatsu H.

Oncol Rep. 1998 May-Jun;5(3):597-600.

PMID:
9538158
16.
17.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

18.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

19.

Potential of antineoplastons in diseases of old age.

Burzynski SR.

Drugs Aging. 1995 Sep;7(3):157-67. Review. No abstract available.

PMID:
8535046
20.

Antiestrogenic piperidinediones designed prospectively using computer graphics and energy calculations of DNA-ligand complexes.

Hendry LB, Chu CK, Copland JA, Mahesh VB.

J Steroid Biochem Mol Biol. 1994 Apr;48(5-6):495-505.

PMID:
8180110

Supplemental Content

Support Center